Latest Articles

Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …

Safety and efficacy of apixaban versus enoxaparin in gynecologic cancer patients undergoing open surgery: an open-label randomized controlled trial.